<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221854</url>
  </required_header>
  <id_info>
    <org_study_id>CCRCSIP</org_study_id>
    <nct_id>NCT04221854</nct_id>
  </id_info>
  <brief_title>Stool-based SDC2 DNA Methylation Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer</brief_title>
  <official_title>Stool-based SDC2 DNA Methylation Test vs. Fecal Immunochemical Test on the Detection of Colorectal Advanced Adenomatous Polyps and Cancer in Chinese Population: A Multi-central Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Municipal Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Nankai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to compare the performance of Stool-based SDC2 DNA Methylation Test
      and commercially available Fecal Immunochemical Test(FIT) , on the detection rate of advanced
      adenomatous polyps and colorectal cancer in Chinese population. Subjects with positive
      results in either test will receive colonoscopy. Lesions will be confirmed as malignant or
      precancerous by colonoscopy and histopathologic examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large cohort of participants will be asked to collect stool sample for either Stool-based
      SDC2 DNA Methylation Test or Fecal Immunochemical Test. Subjects who have positive results
      will undergo colonoscopy within 6 months.

      Representative histopathology slides from tissue biopsied or excised during colonoscopy and
      those from subsequent definitive surgery may be retrieved in order to be evaluated by
      pathologists to confirm the diagnosis and staging.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will received either Stool-based SDC2 DNA Methylation Test or Fecal Immunochemical Test.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Detection Rate of Colorectal Polyps, Advanced Adenomatous Polyps and Cancer by Two Screening Methods</measure>
    <time_frame>One year</time_frame>
    <description>The stool-based SDC2 DNA methylation test CT values of 38 or less compared to beta-actin considered to be positive. Fecal immunochemical test values of more than 100 ng of hemoglobin per milliliter of buffer were considered as positive. An optical colonoscopy is used as diagnostic method. Lesions will be confirmed by histopathologic examination.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colorectal Adenomatous Polyp</condition>
  <condition>Screening</condition>
  <arm_group>
    <arm_group_label>Stool-based SDC2 DNA methylation test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will received the stool-based SDC2 DNA methylation test for the screening of colorectal advanced adenomatous polyps and cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fecal immunochemical test group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will received the fecal immunochemical test for the screening of colorectal advanced adenomatous polyps and cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Stool-based SDC2 DNA methylation test</intervention_name>
    <description>Stool-based SDC2 DNA methylation test</description>
    <arm_group_label>Stool-based SDC2 DNA methylation test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fecal immunochemical test</intervention_name>
    <description>Fecal immunochemical test</description>
    <arm_group_label>Fecal immunochemical test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is average risk for development of colorectal cancer.

          2. Subject is able and willing to undergo a screening colonoscopy within six months of
             enrollment.

          3. Subject is 45 to 80 years of age inclusive.

          4. Subject is able to comprehend, sign, and date the written informed consent document to
             participate in the study.

          5. Subject is able and willing to provide stool samples according to written instructions
             provided to them.

        Exclusion Criteria:

          1. Subject has any condition which, in the opinion of the investigator should preclude
             participation in the study.

          2. Subject has a history of colorectal cancer or adenoma.

          3. Subject has a history of other digestive tract cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Gu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Municipal Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enda Yu, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ximo Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Nankai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shan Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiahua Leng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Xu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pengzhe Qin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Lan, M.D., Ph.D.</last_name>
    <phone>+86-13710316769</phone>
    <email>lanping@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yufeng Chen, MD, PhD</last_name>
    <phone>+86-13710555130</phone>
    <email>chenyf78@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Lan, MD, PhD</last_name>
      <phone>+86-13710316769</phone>
      <email>lanping@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ping Lan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiahua Leng, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jiahua Leng, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shan Wang, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Shan Wang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Center for Disease Control and Prevention</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pengzhe Qin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pengzhe Qin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Xu, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Dong Xu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enda Yu, MBBS</last_name>
    </contact>
    <investigator>
      <last_name>Enda Yu, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhaoshen Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Municipal Center for Disease Control and Prevention</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Gu</last_name>
    </contact>
    <investigator>
      <last_name>Kai Gu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Nankai Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ximo Wang, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ximo Wang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>February 15, 2020</last_update_submitted>
  <last_update_submitted_qc>February 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ping Lan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Colorectal cancer screening</keyword>
  <keyword>SDC2 DNA Methylation</keyword>
  <keyword>Fecal immunochemical test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

